Glatiramer acetate
Glatiramer acetate Basic information
- Product Name:
- Glatiramer acetate
- Synonyms:
-
- GLATIRAMER ACETATE
- l-glutamic acid polymer with l-alanine, l-lysine and l-tyrosine, acetate (salt)
- 511: PN: WO2010103292 PAGE: 64 claiMed sequence
- L-Alanine polyMer with L-GlutaMic Acid L-Lysine L-Tyrosine Acetate
- L-GlutaMic Acid peptide with L-Alanine L-Lysine L-Tyrosine Acetate Salt
- L-Tyrosine polyMer with L-Alanine L-GlutaMic Acid L-Lysine Acetate
- ProtiraMer
- GaltiraMer acetate
- CAS:
- 147245-92-9
- MF:
- C25H45N5O13
- MW:
- 623.66
- EINECS:
- 814-981-5
- Product Categories:
-
- Amino Acids & Derivatives
- Intermediates & Fine Chemicals
- Peptides
- Pharmaceuticals
- API
- Mol File:
- 147245-92-9.mol
Glatiramer acetate Chemical Properties
- Melting point:
- >239°C (dec.)
- storage temp.
- Refrigerator
- solubility
- Methanol (Slightly), Water (Slightly)
- form
- Solid
- color
- White to Off-White
- CAS DataBase Reference
- 147245-92-9(CAS DataBase Reference)
Glatiramer acetate Usage And Synthesis
Originator
Copaxone,Teva Pharmaceuticals,Israel
Uses
Glatiramer Acetate-Dx is labelled Glatiramer Acetate (G406800) which is a random basic synthetic copolymer of L-alanine, L-lysine, l-glutamic acid and L-tyrosine. Glatiramer acetate is an immunomodulator used in treatment of multiple sclerosis.
Uses
Glatiramer acetate is a random basic synthetic copolymer of L-alanine, L-lysine, l-glutamic acid and L-tyrosine in a molar ratio of 6:1.9:4.7:1. Glatiramer acetate is an immunomodulator used in treatment of multiple sclerosis.
Manufacturing Process
Glatiramer Acetate is water soluble copolypeptide with molecular weight
15,000-25,000.
Copolymer is prepared by copolymerization of the N-carboxyanhydrides of
tyrosine, alanine, lysine, and glutamic acid. The polymerisation was carried
out at ambient temperature in anhydrous dioxane with diethylamine as
initiator. Glatiramer Acetate have the ratio alanin:glutamic acid:lysine:tyrosine
= 1:6:4.54:2.
brand name
Copaxone (Teva).
Therapeutic Function
Immunomodulator
Clinical Use
Immunomodulating drug:
Treatment for patients at a high risk of developing
multiple sclerosis and for reduction in relapses in
ambulatory patients
Metabolism
A substantial fraction of a subcutaneous dose of glatiramer is believed to be hydrolysed locally. Some of the injected dose is also presumed to enter the lymphatic system, either intact or partially hydrolysed.
Glatiramer acetateSupplier
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 17721492509
- 643638326@qq.com
- Tel
- sales@boylechem.com
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- 021-50790412
- info@chemvon.com